Treatment of hepatitis C and B virus infection with interferon;Place des interférons dans le traitement des infections par les virus de l'hépatite B et de l'hépatite C

Revue de Medecine Interne

Volumn 23, Issue SUPPL. 4, 2002, Pages

  Cacoub, Patrice ^a   Benhamou, Y ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Hepatitis B virus infection; Hepatitis C virus infection; Interferon alpha; Pegylated alpha interferon; Ribavirine; Treatment

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; HEPATITIS B(E) ANTIBODY; INTERFERON; LAMIVUDINE; MACROGOL; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

BLOOD TOXICITY; CHILDHOOD DISEASE; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MIXED INFECTION; MONOTHERAPY; NAUSEA; NEUTROPENIA; REVIEW; SEROCONVERSION; SKIN MANIFESTATION; SURVIVAL; TREATMENT INDICATION;

EID: 0036854281     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(02)00660-4     Document Type: Article

References (163)

1. Degos F. Hepatitis C and alcohol. J Hepatol 1999;31:113-8.
2. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:1717-22.
3. Anderson S, Nevins CL, Green LK, El-Zimaity H, Anand BS. Assessment of liver histology in chronic alcoholics with and without hepatitis C virus infection. Dig Dis Sci 2001;46:1393-8.
4. Schiff ER. Hepatitis C and alcohol. Hepatology 1997;26(Suppl):39-42.
5. Cromie SL, Jenkins PJ, Bowden DS, Dudley FJ. Chronic hepatitis C: Effect of alcohol on hepatitic activity and viral titre. J Hepatol 1996;25:821-6.
6. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatic C infection. Hepatology 1998;28:805-9.
7. Diehl AM. Nonalcoholic steatohepatitis. Sem Liv Dis 1999;19:221-9.
8. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
9. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and surimposed non-alcoholic fatty liver disease. Liver 2001;21:266-71.
10. Poupon RY, Serfaty LD, Amorim M, Galula G, Chretien Y, Chazouillères O. Combination of steatosis and alcohol intake is the main determinant of fibrosis progression in patients with hepatitis C. Hepatology 1999;30:406 [abstract].
11. Giannini E, Ceppa P, Testa R. Steatosis in chronic hepatitis C: Can weight reduction improve therapeutic efficacy? J Hepatol 2001;35:432-3.
12. Clouston AD, Jonsson JR, Purdie DM, Macdonald GA, Pundeya N, Shorthouse C, et al. Steatosis and chronic hepatitis C: Analysis of fibrosis and stellate cell activation. J Hepatol 2001;34:314-20.
13. Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000;85:498-502.
14. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus (IHIT group). Lancet 1998;352:1426-32.
15. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
16. Manns MP, McHutchison JG, Gordon SC, Rustgi V, Shiffman M, Reindollar R, et al. Peginterferon alpha 2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
17. Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, D'Amicis A, et al. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated wit alcohol consumption: A case-control study. Eur J Epidemiol 1994;10:657-64.
18. Pessione F, Ramond M, Peters L, Barel P, Rueff B, Benhamou JP, et al. Five-year survival predictive factors in 122 patients with alcoholic cirrhosis. Beneficial effect of non-smoking, alcohol hepatitis and abstinence. Hepatology 1998;28:387 [abstract].
19. Pessione F, Ramond MJ, Njapoum C, Duchatelle V, Degott C, Erlinger S, et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001;34:121-5.
20. McCaughan GW, Zekry A. Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transpl. Infect Dis 2000;2:151-2.
21. Pessayre D, Larrey D, Biour M. Drug-induced liver injury. In: Bircher J, Benamou JP, McIntyre N, Rizetto N, Rodes J, editors. Textbook of Clinical Hepatology, 2nd Edition, Vol 2. Oxford: Oxford University Press; 1999. p. 1261-315.
22. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 1998;282:103-7.
23. Zeuzem S, Schmidt JM, Lee JH, Rüster B, Roth WK. Effect of interferon alpha on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996;23:366-71.
24. Manabé N, Chevallier M, Chossegros P, Causse X, Guerret S, Trépo C, et al. Interferon alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: A quantitative histological evaluation. Hepatology 1993;8:1344-9.
25. Duchatelle V, Marcellin P, Giostra E, Pouteau M, Auperin A, Guerret S, et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: Quantitative assement by a morphometric method. J Hepatol 1998;29:20-8.
26. Lindsay KL. Treatment of chronic hepatitis C: Comparative virological response rates among the different interferons. J Hepatol 1999;31(Suppl. 1):232-6.
27. Keeffe EB. Hollinger FB and the Consensus Interferon Study Group. Therapy of hepatitis C: Consensus interferon trials. Hepatology 1997;26(Suppl. 1):101-7.
28. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:1058-61.
29. Thomas HC, Török ME, Fortin DM, Taylor-Robinson SD. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 1999;31(Suppl. 1):152-9.
30. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. J Hepatol 1996;25:591-8.
31. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Rivabirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
32. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alpha 2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
33. Lindsay KL, Trépo C, Heintges T, Shiffman ML, Gordon SC, Schiff ER, et al. A randomized, double-blind trial comparing pegylated interferon alpha 2b to interferon alpha 2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
34. Heathcote J, Shiffman ML, Cooksley GE, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alpha 2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
35. Fried MW, Shiffman ML, Reddy RK, Smith C, Marino G, Goncales Jr F, et al. Pegylated (40 kDa) interferon alpha 2a (Pegasys®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. Gastroenterology 2001;120:55 [abstract].
36. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Sem Liv Dis 2002;22:145-55.
37. Roudot-Thoraval F, Abergel A, Allaert F, Bourlière M, Desmortat H, Fagnani F, et al. Hépavir, première étude observationnelle d'une cohorte de malades traités par interféron alpha 2a en monothérapie. Evaluation de l'asthénie et de ses répercussions sociales. Gastroenterol Clin Biol 2001;25:1061-6.
38. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-12.
39. Musselman DL, Lawson DH, Gumnik JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alpha. N Engl J Med 2001;344:961-6.
40. Talal AH, Weisz K, Hau T, Kreiswirth S, Dietrich DT. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon alpha. Am J Gastroenterol 2001;96:2802-4.
41. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999;30:956-61.
42. Poynard T, McHutchison, Goodman Z, Ling M-H, Albrecht J, for the Algovirc Project Group. Is an « À la carte » combination interferon alpha 2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000;31:211-8.
43. Conférence de Consensus. Paris 2002. Traitement de l'hépatite virale C. Gastroenterol Clin Biol 2002;26(Suppl. B):1-320.
44. Camma C, Giunta M, Chemello L, Alberti A, Toyoda H, Trepo C, et al. Chronic hepatitis C: Interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (Eurohep). Hepatology 1999;30:801.
45. Chemello L, Cavalletto L, Donada C, Bonetti P, Casarin P, Urban F, et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997;113:1654-9.
46. Payen JL, Izopet J, Galindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, et al. Better efficacy of a 12-month interferon alpha 2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter, controlled, randomized trial. Hepatology 1998;28:1680-6.
47. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alpha 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C (IHIT Group). N Engl J Med 1998;339:1493-9.
48. Afdhal N, Flamm S, Imperial JC, Malet PF, Tong M, Herrine SK, et al. Analysis of 40 kDA peginterferon alpha 2a in combination with ribavirin, mycophenolate mofetil, amantadine, or amantadine plus ribavirin in patients that relapsed or did not respond to rebetron therapy: A report of two randomised, multicenter, efficacy and safety studies. Hepatology 2001;34:277 [abstract].
49. Cheng SJ, Bonis PAL, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials. Hepatology 2001;33:231-40.
50. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000;32:630-4.
51. Carlsson T, Lindahl K, Schvarcz R, Wejstal R, Uhnoo I, Shev S, et al. HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin. J Viral Hepat 2000;7:409-13.
52. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-72.
53. Di Bisceglie A, Shindo M, Fong T, Fried M, Swain M, Bergasa N, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992;16:649-54.
54. Querenghi F, Yu Q, Billaud G, Maertens G, Trepo C, Zoulim F. Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy. J Viral Hepat 2001;8:120-31.
55. Saito T, Shinzawa H, Kuboki M, Ishibashi M, Toda H, Okuyama Y, et al. A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 1994;89:681-6.
56. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alpha 2b versus no treatment. Hepatology 1999;29:1870-5.
57. Shiratori Y, Moriyama M, Imazeki F, Ohkubo H, Tanaka N, Arakawa Y, et al. A prospective study of interferon therapy modified by pre-treatment viral load in cirrhotic patients. Liver 2000;20:271-80.
58. Everson GT, Jensen DM, Craig JR, van Leeuwen DJ, Bain VG, Ehrinpreis MN, et al. Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics, or nonfibrotics. Hepatology 1999;30:271-6.
59. Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Hollander A, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials. Gastroenterology 1999;117:408-13.
60. Idilman R, De Maria N, Colantoni A, Dokmeci A, Van Thiel DH. Interferon treatment of cirrhotic patients with chronic hepatitis C. J Viral Hepat 1997;4:81-91.
61. Saito T, Shinzawa H, Kuboki M, Ishibashi M, Toda H, Okuyama Y, et al. A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 1994;89:681-6.
62. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
63. Furusyo N, Hayashi J, Ueno K, Sawayama Y, Kawakami Y, Kishihara Y, et al. Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis. Clin Ther 1997;19:1352-67.
64. Ikeda K, Kumada H, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, et al. A randomized controlled trial of interferon alpha in patients with cirrhosis caused by 2a/2b genotype hepatitis C virus. J Hepatol 1998;28:910-1.
65. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis. 1999;19(Suppl. 1):57-65.
66. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2001;34:245 [abstract].
67. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40.
68. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83:901-9.
69. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196-7.
70. Bemardinello E, Cavalletto L, Chemello L, Mezzocolli I, Donada C, Benvegnu L, et al. Long-term clinical outcome after beta interferon therapy in cirrhotic patients with chronic hepatitis C. Hepatogastroenterology 1999;46:3216-22.
71. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol 2001;34:593-602.
72. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor. A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-32.
73. Jaeckel E, Comberg M, Wedemeyer H, Santantonio T, Mayer J, Zakel M, et al. Treatment of acute hepatitis C with interferon alpha 2b. N Engl J Med 2001;345:1452-7.
74. Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001;34:223-9.
75. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update. J Viral Hepat 2001;8:48-62.
76. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al. Interferon for interferon naive patients with chronic hepatitis C (Cochrane Review). Cochrane Database Syst Rev 2002;2:CD 000370.
77. Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci 1996;41:1248-55.
78. Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allinger S, et al. High-dose interferon alpha 2b treatment prevents chronicity in acute hepatitis C: A pilot study. Dig Dis Sci 1996;4(12 Suppl):81-5.
79. Gerlach TJ, Zachoval R, Gruener N, Jung MC, Ulsenheimer A, Schraut W, et al. Acute hepatitis C: Natural course and response to antiviral treatment. Hepatology 2001;34:341 [abstract].
80. Santantonio T, Mazzola M, Guastadisegni A, Casalino C, Pastore G. A cohort study of acute hepatitis C virus (HCV) infection: Natural course and outcome. Hepatology 1999;30:205 [abstract].
81. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-14.
82. Giuberti T, Marin MG, Ferrari C, Marchelli S, Schianchi C, Degli Antoni AM, et al. Hepatitis C virus viremia following clinical resolution of acute hepatitis C. J Hepatol 1994;20:666-71.
83. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001;33:321-7.
84. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, et al. Interferon alpha 2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-7.
85. Casato M, Agnello V, Pucillo LP, Knight GB, Leoni M, Del Vecchio S, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997;90:3865-73.
86. Dammaco F, Sansonno D, Han JH, Shyamala V, Comacchiulo V, Iacobelli AR, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: A long-term, randomized, controlled study. Blood 1994;84:3336-43.
87. Durand JM, Cacoub P, Lunel-Fabiani F, Cretel E, Kaplanski G, Cosserat J, et al. Ribavirin in hepatitis C related cryoglobulinemia. J Rheumatol 1998;25:1115-7.
88. Cohen P, Nguyen QT, Dény P, Ferrière F, Roulot D, Lotholary O, et al. Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. Ann Med Interne 1996;147:81-6.
89. Mazzaro C, Carniello GS, Colle R, Doretto P, Mazzi G, Crovatto M, et al. Interferon alpha therapy in HCV-positive mixed cryoglobulinemia: Viral and host factors contributing to efficacy of the therapy. Ital J Gastroenrol Hepatol 1997;29:343-50.
90. Adinolfi LE, Utili R, Zampino R, Ragone E, Moromone G, Ruggiero G. Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinemia. Eur J Gastroenterol Hepatol 1997;9:1067-72.
91. Ferri C, Marzo E, Longombardo G, Lombardini F, La Civita L, Venacore R, et al. Interferon alpha in mixed cryoglobulinemia patients: A randomized, crossover-controlled trial. Blood 1993;81:1132-6.
92. Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon alpha. J Rheumatol 2000;27:2172-8.
93. Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic P. Long term efficacy of interferon alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 2001;28:2466-7.
94. Cacoub P, Lidove O, Hausfater P, Maisonobe T, Thibault V, Charlotte F, et al. Antiviral treatment and outcome in patients with hepatitis C virus systemic vasculitis. Arthritis Rheum 2001;44(Suppl):56.
95. Cacoub P, Maisonobe T, Thibault V, Gatel A, Servan J, Musset L, et al. Systemic vasculitis in patients with hepatitis C. J Rheumatol 2001;28:109-18.
96. D'Amico G, Fornasieri A. Cryoglobulinemia. In: Brady HR, Wilcox CS, editors. Therapy in Nephrology and Hypertension. Philadelphia: Saundens Co; 1999.
97. Gumber SC, Chopra SC. Hepatitis C: A multifaced disease. Review of extrahepatic manifestations. Ann Intern Med 1995;123:615-20.
98. Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: A report of 239 hepatology clinic patients. Am J Gastroenterol 1999;94:1355-60.
99. Carithers RL, Sugano D, Bayliss M. Health assessment for chronic HCV infection: Results of quality of life. Dig Dis Sci 1996;41:75-80.
100. Sladden TJ, Hickey AR, Dunn TM, Beard JR. Hepatitis C virus infection: Impacts on behaviour and lifestyle. Aust N Z J Public Health 1998;22:509-11.
101. Bayliss M, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware Jr. JE. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998;7:39-55.
102. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999;30:1299-301.
103. Ware JE, Bungay K, Gandek B, Bayliss M. Assessment of the health-related quality of life (HQL) of patients with chronic hepatitis C (CHC). Gastroenterology 1994;106:393 [abstract].
104. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-12.
105. Cacoub P, Ratziu V, Ghillani P, Thibault V, Charlotte F, Piette JC, et al. Natural history and treatment impact on fatigue in patients with chronic hepatitis C: A follow up in 425 patients. Arthritis Rheum 2001;44(Suppl):350.
106. Bonkovsky HL, Woolley JM, the Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999;29:264-70.
107. Ware JE, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999;30:550-5.
108. Hausfater P, Cacoub P, Rosenthal E, Bernard N, Loustaud-Ratti V, Le Lostec Z, et al. Hepatitis C virus infection and lymphoproliferative diseases in France: A national study. The Germivic Group. Am J Hematol 2000;64:107-11.
109. Hausfater P, Cacoub P, Sterkers Y, Thibault V, Amoura Z, Nguyen L, et al. Hepatitis C virus infection and lymphoproliferative diseases: Prospective study on 1.576 patients in France. Am J Hematol. 2001;67:168-71.
110. Hermine O, Lefrère F, Bronowicki JP, Mariette X, Jondeau K, Cacoub P, et al. Splenic lymphoma with villous lymphocytes may be associated with hepatitis C: Epidemiologic and therapeutic evidence. Blood 1999;10(Suppl. 1):2932.
111. Jaccard A, Loustaud V, Turlure P, Rogez S, Bordessoule D. Ribavirin and immune thrombocytopenic purpura. Lancet 1998;351:1660-1.
112. Cacoub P, Ratziu V, Myers RP, Ghillani P, Piette JC, Moussali J, et al. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol 2002 in press.
113. Cacoub P, Sbai A, Frances C, Genesti C, Hausfater P, Piette JC. Sarcoidose systémique après traitement par interféron alpha pour une hépatite C. Gastroenterol Clin Biol 2000;24:364-6.
114. Lidove O, Cacoub P, Hausfater P, Sbai A, Léger JM, Frances C, et al. Cryoglobulinémie et hépatite C: Aggravation de la multinévrite après interféron alpha (quatre cas. Gastroenterol Clin Biol 1999;23:403-6.
115. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996;23:1117-25.
116. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994;84:1020-3.
117. Thomas DL, Shih JW, Alter HJ, Vlahov D, Cohn S, Hoover DR, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690-5.
118. Soto B, Rodrigo L, Garcia-Bengoechea M, Sanchez-Quijano A, Riestra S, Arenas JI, et al. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case. A multicentre study of 423 pairings. J Intern Med 1994;236:515-9.
119. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutelier A, et al. Liver fibrosis progression in HIV-HCV coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8.
120. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, et al. Care of patients with chronic hepatitis C and HIV co-infection: Recommendation from the HIV-HCV international panel. AIDS 2002;16:1-16.
121. Di Martino V, Eznfis J, Tainturier M-H, Benhamou Y, Bochet M, Opolon P, et al. Impact of HIV coinfection on the long-term follow-up of HCV-related cirrhosis. Hepatology 2000;32:212 [abstract].
122. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001;345:211-4.
123. Perez-Olmeda M, Gonzalez J, Garcia-Samaniego J, Arribas JR, Pena JM, Soriano V. Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. JAIDS 1999;22:308-9.
124. Landau A, Batisse D, Duong Van Huyen JP, Piketty C, Bloch F, Pialoux G, et al. Efficacy and safety of combination therapy with interferon alpha 2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000;14:839-44.
125. Zyberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: An early report. Gut 2000;47:694-7.
126. Nasti G, Di Gennaro G, Tavio M, Cadorin L, Tedeschi RM, Talamini R, et al. Chronic hepatitis C in HIV infection: Feasibility and sustained efficacy of therapy with interferon alpha 2b and ribavirin. AIDS 2001;15:1783-7.
127. Sauleda S, Juarez A, Esteban I, Altisent C, Ruiz I, Puig L, et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 2001;5:1035-40.
128. Landau A, Batisse D, Piketty C, Duong Van Huyen JP, Bloch F, Belec L, et al. Long-term efficacy of combination therapy with interferon alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001;15:2149-55.
129. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondiral toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357:208-81.
130. Salmon-Céron D, Chauvelot-Moachon L, Abad S, Silbermann B, Sogni P. Mitochondrial toxic effects and ribavirin. Lancet 2001;357:1802-3.
131. Aach RD, Yomtovian RA, Hack M. Neonatal and pediatric post transfusion hepatitis C: A look back and a look forward. Pediatrics 2000;105:836-42.
132. Matsuoka S, Tatara K, Hayabuchi Y, Taguchi Y, Mori K, Honda H, et al. Serologic, virologic and histologic characterisation of chronic phase hepatitis C virus disease in children infected by transfusion. Pediatrics 1994;94:919-22.
133. Garcia-Monzon C, Jara P, Fernandez-Bermejo M, Hierro L, Frauca E, Camarena C, et al. Chronic hepatitis C in children: A clinical and immunohistochemical comparative study with adult patients. Hepatology 1998;28:1696-701.
134. Locasciulli A, Testa M, Pontisso P, Benvegnu L, Fraschini D, Corbetta A, et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood 1997;90:4628-33.
135. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood donor screening. N Engl J Med 1999;341:866-70.
136. Strickland DK, Riely CA, Patrick CC, Jones-Wallace D, Boyett JM, Waters B, et al. Hepatitis C infection among survivors of childhood cancer. Blood 2000;95:3065-70.
137. Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002;34:52-8.
138. Lackner H, Benesch M, Schagerl S, Kerbl R, Schwinger W, Urban C. Interferon alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000;106:53.
139. Christensson B, Wiebe T, Akesson A, Widell A. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Inf Dis 2000;30:585-6.
140. Bortolotti F, Resti M, Giacchino R, Crivellaro C, Zancan L, Azzari C, et al. Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus. J Pediatr 1998;130:990-3.
141. Etani Y, Tajiri H, Tada K, Sawada A, Kozaiwa K, Okada S, et al. Molecular diagnosis and liver histology of children with mother-to-child-transmitted hepatitis C virus infection. J Pediatr 1998;133:588.
142. Palomba E, Manzini P, Fiammengo P, Mademi P, Saracco G, Tovo PA. Natural history of perinatal hepatitis C virus infection. Clin Infect Dis 1996;23:47-50.
143. Zanetti AR, Tanzi E, Romano L, Zuin G, Minola E, Vecchi L, et al. A prospective study of mother-to-infant transmission of hepatitis C virus. lntervirol 1998;41:208-12.
144. Li R, Sugiyama K, Goto K, Miyake Y, Wada Y. Homology of E2 gene in 8 child-mother pairs infected with hepatitis C virus. Tohoku J Exp Med 1997;183:197-210.
145. Wirth S, Gehring S, Gerner P, Kulmer U. Alpha interferon 2b and ribavirin treatment in children with chronic hepatitis C infection. Hepatology 2001;34:333A.
146. Lok ASF. Hepatitis B infection: Pathogenesis and management. J Hepatol 2000;32:89-97.
147. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha interferon treatment in patients with hepatitis Be antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
148. Lok AS. Treatment of chronic hepatitis B. J Viral Hepat 1994;1:105-24.
149. Carreno V, Marcellin P, Hadziyannis S, Salmeron J, Diago M, Kitis GE, et al. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (Eurohep). Hepatology 1999;30:277-82.
150. Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat 2001;8:311-21.
151. Pastore G, Santantonio T, Milella M, Monno L, Mariano N, Moschetta R, et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992;14:221-5.
152. Brunetto MR, Oliveri F, Colombatto P, Capalbo M, Barbera C, Bonino F. Treatment of chronic anti-HBe-positive hepatitis B with interferon alpha. J Hepatol. 1995;22:42-4.
153. Fattovich G, McIntyre G, Thursz M, Colman K, Giuliano G, Alberti A, et al. Hepatitis B virus precore/core variation and interferon therapy. Hepatology 1995;22:1355-62.
154. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
155. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis Be antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-32.
156. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-96.
157. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51.
158. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-32.
159. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al.
160. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6.
161. + chronic hepatitis B. Hepatology 2001;4:340 [abstract].
162. Hadziyannis SJ. A double-blind, randomized, placebo-controlled study of adefovir dipivoxil (adv) for presumed precore mutant chronic hepatitis B: 48 Week results. J Hepatol 2002 in press.
163. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 2001;358:718-23.